The Circulating Levels of Complement-C1q/TNF-Related Protein 13 (CTRP13) in Patients with Type 2 Diabetes and its Association with Insulin Resistance
The Circulating Levels of Complement-C1q/TNF-Related Protein 13 (CTRP13) in Patients with Type 2 Diabetes and its Association with Insulin Resistance
复制标题
DOI：
10.7754/clin.lab.2016.160609
复制
发表时间：
2017-01-01
影响因子：
0.7
通讯作者：
Shanaki, Mehrnoosh
中科院分区：
文献类型：
--
作者：
Afrookhteh, Abolfazl;Emamgholipour, Solaleh;Shanaki, Mehrnoosh
背景：补体- c1q / tnf相关蛋白13 （CTRP13）是一种参与能量代谢调节的新型脂肪因子。在这里，我们试图评估2型糖尿病（T2D）患者（n = 40）和健康受试者（n = 40）的血清CTRP13和脂联素水平，并研究CTRP13水平与糖尿病相关指标的关系。方法：采用酶联免疫吸附试验（ELISA）检测t2dm患者（n = 40）和年龄、性别匹配对照组（n = 40）的循环CTRP13和脂联素水平。对所有受试者进行人体测量和生化评价。结果：t2dm患者循环CTRP13和脂联素水平明显低于对照组（p = 0.025和p < 0.001）。CTRP13与空腹血糖（Spearman’s p = -0.420, p < 0.001）、HbA1C （Spearman’s p = -0.554, p < 0.001）、HOMA-IR （Spearman’s p = -0.403, p < 0.001）呈负相关。ROC曲线分析显示，CTRP13可作为T2D患者与健康个体的生物标志物（曲线下面积，95%可信区间= 0.841,0.752 - 0.929）。CTRP13水平等于或低于0.885 ng/mL是鉴别t2dm患者与健康人的最佳临界值（敏感性= 92.5%，特异性= 70%，约登指数= 0.625）。结论：CTRP13似乎是一种与人类T2D相关的新型脂肪因子，因为它在T2D患者的血清水平明显较低，并且与人类胰岛素抵抗和FBS呈负相关。
Background: Complement-C1q/TNF-related protein 13 (CTRP13) is a novel adipokine involved in the regulation of energy metabolism. Here, we sought to evaluate serum levels of CTRP13 and adiponectin in patients with type 2 diabetes (T2D) (n = 40) and healthy subjects (n = 40) and also to study the association of CTRP13 levels with diabetes-related indices.Methods: Circulating levels of CTRP13 and adiponectin were measured by enzyme-linked immunosorbent assay (ELISA) in T2D patients (n = 40) and in an age and gender-matched control group (n = 40). The anthropometric assessment and biochemical evaluation were done in all subjects.Results: Circulating levels of CTRP13 and adiponectin were significantly lower in T2D patients in comparison with controls (p = 0.025 and p < 0.001, respectively). CTRP13 was inversely correlated with fasting blood sugar (Spearman's p = -0.420, p < 0.001), HbA1C (Spearman's p = -0.554, p < 0.001), and HOMA-IR (Spearman's p = -0.403, p < 0.001). ROC curve analysis showed that CTRP13 might be used as a biomarker for differentiating T2D patients from healthy individuals (area under the curve with 95% confidence intervals = 0.841, 0.752 - 0.929). A CTRP13 level equal to or lower than 0.885 ng/mL was found to be the optimal cutoff (sensitivity = 92.5%, specificity = 70%, Youden Index = 0.625) for differentiating T2D patients from healthy individuals.Conclusions: It appears that CTRP13 is a novel adipokine associated with T2D in humans as its serum level was significantly lower in T2D patients and also was inversely correlated with insulin resistance and FBS in humans.